NCT07680335 · RECRUITING
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease
This trial is testing whether blood tests for Alzheimer's-related proteins, specifically p-tau217 and neurofilament light chain, can help memory clinic doctors make faster and more accurate diagnoses. Researchers want to know if having these blood results changes a doctor's diagnosis, confidence level, or care plan for patients with cognitive complaints. This is a Phase NA study, meaning it is a practical clinical implementation study rather than a drug trial.
You may qualify if
- Patient presents in memory clinic with cognitive complaints.
- The physician is concerned about underlying AD as etiology of the complaints.
- Adequate fluency in Dutch to understand informed consent procedure.
You're excluded if
- Age under 55.
- Previous biomarker-confirmed diagnosis of AD.
- Alcohol or drug abuse to such an extent that treatment would be advisable.
- Patient is incapacitated, and is not able to judge consequences of participation.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-07-02